Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape

References

• Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget. 2010;1:246–251.
   PubMedGoogle Scholar
• Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785–2808.
   PubMed Web of Science ®Google Scholar
• Patil MD, Bhaumik J, Babykutty S, et al. Arginine dependence of tumor cells: targeting a chink in cancer’s armor. Oncogene. 2016;35:4957-4972.
   Web of Science ®Google Scholar
• Pasut G, Anti-Cancer SM. PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev. 2008;60:69–78.
   PubMed Web of Science ®Google Scholar
• Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003;55:1293–1302.
   PubMed Web of Science ®Google Scholar
• Delage B, Fennell DA, Nicholson L, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126:2762–2772.
   PubMed Web of Science ®Google Scholar
• Xiong L, Teng JLL, Botelho MG, et al. Arginine metabolism in bacterial pathogenesis and cancer therapy. Int J Mol Sci. 2016;17:363–381.
   PubMed Web of Science ®Google Scholar
• Feun L, You M, Wu CJ, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des. 2008;14:1049–1057.
   PubMed Web of Science ®Google Scholar
• Bragg J, Rajkovic A, Anderson C, et al. Identification and characterization of a putative arginine kinase homolog from Myxococcus xanthus Required for fruiting body formation and cell differentiation. J Bacteriol. 2012;194:2668–2676.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kashiwagi SJR. The role of nitric oxide in tumor progression. Nat Rev Cancer. 2006;6:521–534.
   PubMed Web of Science ®Google Scholar
• Takaku H, Takase M, Abe S, et al. In vivo anti-tumor activity of arginine deiminase purified. Int J Cancer. 1992;51:244–249.
   PubMed Web of Science ®Google Scholar
• Cheng PN-M, Lam T-L, Lam W-M, et al. Pegylated Recombinant Human Arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67:309–317.
   PubMed Web of Science ®Google Scholar
• Tommasi S, Elliot DJ, Da BM, et al. Homoarginine and inhibition of human arginase activity : kinetic characterization and biological relevance. Sci Rep. 2018;8:3697.
   Web of Science ®Google Scholar
• Li L, Wang Y, Chen J, et al. An engineered arginase FC protein inhibits tumor growth in vitro and in vivo. evidence-based complement. Evid Based Complement Alternat Med. 2013;2013.
   Google Scholar
• Stone EM, Glazer ES, Chantranupong L, et al. Replacing Mn2+ with Co2+ in human arginase i enhances cytotoxicity toward L-arginine auxotrophic cancer cell lines. ACS Chem Biol. 2010;5:333–342.
   PubMed Web of Science ®Google Scholar
• Wheatley DN, Campbell E. Arginine catabolism, liver extracts, and cancer. Pathol Oncol Res. 2002;8:18–25.
   PubMedGoogle Scholar
• Han RZ, Xu GC, Dong JJ, et al. Arginine deiminase : recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug. Appl Microbiol Biotechnol. 2016;4747–4760.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Takaku H, Umeda M, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a mycoplasma-infected cell line. Cancer Res. 1990;50:4522–4527.
   PubMed Web of Science ®Google Scholar
• Agency of Ind Science & Technol. Arginine deiminase and use thereof. JP2035081. 1988.
   Google Scholar
• Nippon Mining Company Limited, Tokyo. Arginine deiminase from a mycoplasma arginini strain. US5474928. 1995.
   Google Scholar
• Enzon I, Piscataway NJU Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same. US6132713. 1997.
   Google Scholar
• Phoenix Pharmacologics Inc., Lexington K Modified arginine deiminase. US6737259. 2004.
   Google Scholar
• Coriell Institute for Medical Research. Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent. US5372942A. 1992.
   Google Scholar
• Cancer Treatments International. Therapeutic composition for treatment of cancer by arginine depletion. EP1499342. 2005.
   Google Scholar
• Tepic S, Pyk P. Arginine decomposing enzyme therapeutic composition. US6261557. 2001.
   Google Scholar
• Shanghai Institute of Pharmaceutical Industry, CN, China Head Institute Of Pharmaceutical Industrial Research. Arginine deiminase mutant from arthritis-type mycoplasma and application thereof. CN104130996. 2014.
   Google Scholar
• Ikemoto M, Tabata M, Miyake T, et al. Expression of human liver arginase in Escherichia coli. Purification and properties of the product. Biochem J. 1990;270:697–703.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu J, Yu X, et al. High-level expression of human arginase I in Pichia pastoris and its immobilization on chitosan to produce L-ornithine. BMC Biotechnol. 2015;15:66.
   PubMed Web of Science ®Google Scholar
• The University of Taxas System. Compositions and methods for engineered human arginine deiminases. US20090238813. 2009.
   Google Scholar
• Jiangsu T-Mab Biopharma Co. Ltd. Arginine deiminase mutant and preparation and application thereof. US 8663967. 2011.
   Google Scholar
• RWTH Aachen University, Jacob’s University Bremen GmbH. Directed evolution of arginine deiminase for increased activity at physiological pH. EP2295560. 2011.
   Google Scholar
• Vision Global Holdings Ltd., Sheung WH. Albumin-binding arginine deiminase and the use thereof. US9255262. 2016.
   Google Scholar
• Fernandes HS, Teixeira CSS, Fernandes P, et al. Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections. Expert Opin Ther Pat. 2017;27:283–297.
   PubMed Web of Science ®Google Scholar
• Long Y, Tsai W, Wangpaichitr M, et al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence and glutamine addiction. Mol Cancer Ther. 2013;12:2581–2590.
   PubMed Web of Science ®Google Scholar
• Huang H, Wu W, Wang Y, et al. ASS1 as a novel tumor suppressor gene in myxo fibrosarcomas : aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19:2861-2872.
   Web of Science ®Google Scholar
• Aerase Inc. Compositions of engineered human arginases and methods for treating cancer. US9050340. 2015.
   Google Scholar
• Jiangsu Simcere Pharmaceutical Research Company Ltd. Recombinant human arginase fusion protein and application thereof. CN101781369. 2010.
   Google Scholar
• R The Board of Regents of The University of Texas System. Compositions of engineered human arginases and methods for treating cancer. WO2010051533A2. 2008.
   Google Scholar
• Turecek PL, Bossard MJ, Schoetens F, et al. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm. 2016;105:460–475.
   PubMed Web of Science ®Google Scholar
• Takaku H, Misawa S, Hideya Hayashi KM. Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini. Jpn J Cancer Res. 1993;84:1195–1200.
   PubMedGoogle Scholar
• Enzon Pharmaceuticals Inc. Modified arginine deiminase. AU1998074798. 1999.
   Google Scholar
• Shanghai Fudan Zhangjiang Biol. Modified arginine deiminase. CN1536079. 2003.
   Google Scholar
• Tsinghua University Protgen Ltd. Novel compound for the treatment of tumor. US20100303893. 2010.
   Google Scholar
• Jiangnan University C. PEG (polyethylene glycol) modified recombinant arginine deiminase (ADI) as well as preparation method and application thereof. CN103923898. 2014.
   Google Scholar
• Bio-Cancer Treatment International Ltd. Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation. US7951366. 2002.
   Google Scholar
• The Hong Kong Polytechnic University. Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents. US8507245. 2013.
   Google Scholar
• Beijing Shuanglu Pharmaceutical Co. Ltd. Sulfhydryl modified recombinant human arginase I, as well as preparation method and application thereof. CN103571814. 2012.
   Google Scholar
• Bio-Cancer Treatment International Limited. Use of arginase in combination with 5FU and other compounds for treatment of human malignancies. WO2006058486. 2006.
   Google Scholar
• Polaris Group. Methods of treatment with arginine deiminase. US9333268. 2016.
   Google Scholar
• Srl M. Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria. US20030215429. 1998.
   Google Scholar
• Pharma E. Erythrocytes containing arginine deiminase. US9125876. 2015.
   Google Scholar
• Jiangsu T-Mab Biopharma Co. Ltd. Arginine deiminase mutant and preparation and application thereof. CN101812438. 2010.
   Google Scholar
• Phoenix Pharmacologics Inc. Methods for inhibiting viral replication in vivo. US7204980. 2007.
   Google Scholar
• AngioLab Inc. Pharmaceutical composition comprising arginine deiminasa for inhibiting angio-genesis. US20040096437. 2004.
   Google Scholar
• US Department of Health and Human Services, National Institute of Health, Division of Extramural Inventions and Technology Resources. Methods for treatment of ocular diseases. US8877183. 2014.
   Google Scholar
• Foster TP, Rodriguez PC, Hill JM, et al. Methods for treatment of ocular diseases. WO2014003850. 2014.
   Google Scholar
• Louisiana State University and Agricultural and Mechanical College. Methods for treatment of ocular diseases. US20130344049. 2014.
   Google Scholar
• Bio cancer Treatment International. Methods and compositions for modulating the immune system with arginase. WO2015165374. 2014.
   Google Scholar
• Wells JW, Evans CH, Scott MC, et al. Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation. PLoS One. 2013;8:1.
   Web of Science ®Google Scholar
• Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006;15:815–822.
   PubMedGoogle Scholar